Although further measurements of synaptic indicators such as PSD-95 and synaptophysin will be important for illustrating synaptic repair and will be conducted in future studies, the LTP data described above suggest that FK506 may not only mitigate TauO-associated cognitive impairments but also contribute to the restoration of normal synaptic function, providing further evidence for the therapeutic potential of CaN inhibition in the context of AD pathology. This evidence concerns the gene NUP214 and Cognitive impairment.